Compare YJ & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | LGVN |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.8M |
| IPO Year | 2019 | 2021 |
| Metric | YJ | LGVN |
|---|---|---|
| Price | $1.25 | $1.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | ★ 322.8K | 67.8K |
| Earning Date | 08-20-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | $46.15 |
| Revenue Next Year | N/A | $396.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $0.48 |
| 52 Week High | $13.97 | $7.60 |
| Indicator | YJ | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 38.44 |
| Support Level | N/A | $0.61 |
| Resistance Level | $1.51 | $7.30 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 2.28 | 33.33 |
Yunji Inc is a social e-commerce platform in China using a membership-based model that leverages the power of social interaction. The group offers high-quality products at attractive prices and incentivizes members to promote its platform and share products with their social contacts. It empowers prime emerging brands and manufacturers with a deep understanding of market trends and customer behavior to produce high-quality products to meet the demands of members. The company also developed several private labels in the mass consumption field, which are sold on its own platform as well as offered and sold through external channels. It operates in the PRC, and substantially all the Group's revenue is derived from within the PRC.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.